This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients

The study includes the following sequential phases: Screening, Apheresis and A-CAR028 manufacturing, Baseline testing, Lymphodepletion, A-CAR028 infusion, Dose-limiting toxicity observation and Follow-up Visit

Inclusion Criteria:

• 18 to 75 years old at the time of signing the Informed Consent Form (ICF)
• More than 12 weeks of expected survival
• ECOG score 0 or 1
• Relapsed or refractory AML
• Adequate organ function

Exclusion Criteria:

• Acute Promyelocytic Leukemia (APL)
• Mixed Phenotype Acute Leukemia (MPAL)
• Acute Undifferentiated Leukemia (AUL)
• Only extramedullary leukemia
• Known allergies to the components or excipients of the A-CAR028 cell product
• Severe heart diseases, including but not limited to, myocardial infarction, angioplasty or stent implantation within 12 months prior to signing the ICF, unstable angina pectoris, severe arrhythmia, history of severe non-ischemic cardiomyopathy, heart failure
• Autologous or allogeneic hematopoietic stem cell transplantation within 3 months prior to signing the ICF
• Central nervous system (CNS) involvement or symptoms of CNS involvement (including cranial nerve lesions and extensive lesions or spinal cord compression)
• A stroke or seizure occurred within 12 months prior to signing the ICF
• Malignancy history within 5 years prior to signing the ICF
• Uncontrolled active infection
• Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive
• Live vaccine injection within 4 weeks prior to signing the ICF
• Acute or chronic graft-versus-host disease (GVHD) was present at screening
• Inadequate washing time for previous treatment
• Previously treated with CAR-T cell products or genetically modified T cell therapies